Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI
Liver International · 2023-11 · 43 (11) · 2523-2537
DOI: 10.1111/liv.15715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 28.08.2023. Verfasst von Xianjun Xu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Signal Transduction, Transforming Growth Factor beta. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Purpose Liver fibrosis is a wound‐healing reaction that eventually leads to cirrhosis. Hydronidone is a new pyridine derivative with the potential to treat liver fibrosis. In this study, we explored the antifibrotic effects of hydronidone and its potential mode of action.
Methods
The anti‐hepatic fibrosis effects of hydronidone were studied in carbon tetrachloride (CCl 4 )‐ and 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine (DDC)‐ induced animal liver fibrosis. The antifibrotic mechanisms of hydronidone were investigated in hepatic stellate cells (HSCs). The antifibrotic effect of hydronidone was further tested after Smad7 knockdown in HSCs in mouse models of fibrosis.
Results
In animal models, hydronidone attenuated liver damage and collagen accumulation, and reduced the expression of fibrosis‐related genes. Hydronidone decreased the expression of fibrotic genes in HSCs. Impressively, hydronidone significantly upregulated Smad7 expression and promoted the degradation of transforming growth factor β receptor I (TGFβRI) in HSCs and thus inhibited the TGFβ‐Smad signalling pathway. Specific knockdown of Smad7 in HSCs in vivo blocked the antifibrotic effect of hydronidone.
Conclusion
Hydronidone ameliorates liver fibrosis by inhibiting HSCs activation via Smad7‐mediated TGFβRI degradation. Hydronidone is a potential drug candidate for the treatment of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Pancreatic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Huaian First People's Hospital, Nanjing Medical University, Huaian, China.
- Continent Pharmaceuticals Co., Ltd., Beijing, China.
ORCID-Profile: Lungen Lu
Zitieren
APA
Xu, X., Guo, Y., Luo, X., Shen, Z., Sun, Z., Shen, B., Zhou, C., Wang, J., Lu, J., Zhang, Q., Ye, Y., Luo, Y., Qu, Y., Cai, X., Dong, H., & Lu, L. (2023). Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI. Liver International, 43(11), 2523-2537. https://doi.org/10.1111/liv.15715
Vancouver
Xu X, Guo Y, Luo X, Shen Z, Sun Z, Shen B, et al. Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI. Liver International. 2023;43(11):2523-2537. doi:10.1111/liv.15715
BibTeX
@article{Xu2023,
author = {Xu, Xianjun and Guo, Yuecheng and Luo, Xin and Shen, Zhenyang and Sun, Zhongshang and Shen, Bo and Zhou, Cui and Wang, Junjun and Lu, Jingyi and Zhang, Qingqing and Ye, Yanping and Luo, Ying and Qu, Ying and Cai, Xiaobo and Dong, Hui and Lu, Lungen},
title = {Hydronidone ameliorates liver fibrosis by inhibiting activation of hepatic stellate cells via Smad7‐mediated degradation of TGFβRI},
journal = {Liver International},
year = {2023},
volume = {43},
number = {11},
pages = {2523--2537},
doi = {10.1111/liv.15715}
}
EUVIMED